At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
IBB iShares Biotechnology ETF
Not Yet Opened 10-23 16:00:00 EDT
207.74
-1.80
-0.86%
盘后207.74
+0.000.00%
19:30 EDT
High208.71Low205.96Vol830.36K
Open208.60D1 Closing209.54Amplitude1.31%
Mkt Cap10.70BTradable Cap10.70BTotal Shares51.50M
T/O172.42MT/O Rate1.61%Tradable Shares51.50M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Amgen (AMGN) Posts Phase 3 Lung Cancer Data With 58% Lower Death Risk
Simply Wall St.  ·  13:29
Amgen (AMGN) Posts Phase 3 Lung Cancer Data With 58% Lower Death Risk
Kidney Trial Win Could Be A Game Changer For Vertex Pharmaceuticals (VRTX)
Simply Wall St.  ·  13:25
Kidney Trial Win Could Be A Game Changer For Vertex Pharmaceuticals (VRTX)
Amgen Potential $5 Billion Drug Emerges? JPMorgan Keeps Neutral Rating: A Good Drug Does Not Equal a Good Entry Point
Stock News  ·  12:12
Amgen Potential $5 Billion Drug Emerges? JPMorgan Keeps Neutral Rating: A Good Drug Does Not Equal a Good Entry Point
Vitrafy Life Sciences Sets Investor Briefing for Q1 FY2027 Results
TIPRANKS  ·  11:07
Vitrafy Life Sciences Sets Investor Briefing for Q1 FY2027 Results
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX) and Boston Scientific (BSX)
TIPRANKS  ·  10:20
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX) and Boston Scientific (BSX)
Analysts Offer Insights on Healthcare Companies: CSL (OtherCMXHF), Ascendis Pharma (ASND) and Amgen (AMGN)
TIPRANKS  ·  08:20
Analysts Offer Insights on Healthcare Companies: CSL (OtherCMXHF), Ascendis Pharma (ASND) and Amgen (AMGN)
Amgen announces Phase 3 results of Imdelltra with AstraZeneca’s Imfinzi
TIPRANKS  ·  05:15
Amgen announces Phase 3 results of Imdelltra with AstraZeneca’s Imfinzi
Regeneron announces longer-term data for Phase 2 C-POST trial of Libtayo
TIPRANKS  ·  05:00
Regeneron announces longer-term data for Phase 2 C-POST trial of Libtayo
What Regeneron Pharmaceuticals Buyers Were Betting On
Simply Wall St.  ·  10-25 17:37
What Regeneron Pharmaceuticals Buyers Were Betting On
Regeneron Pharmaceuticals - Libtayo Achieves 37% Reduction in Risk of Death at 44 Months (Hr: 0.63)
THOMSON REUTERS  ·  10-25 17:16
Regeneron Pharmaceuticals - Libtayo Achieves 37% Reduction in Risk of Death at 44 Months (Hr: 0.63)
Regeneron Pharmaceuticals - Libtayo Confirms Sustained Disease-Free Survival Benefit Including Mrd Negative Patients
THOMSON REUTERS  ·  10-25 17:16
Regeneron Pharmaceuticals - Libtayo Confirms Sustained Disease-Free Survival Benefit Including Mrd Negative Patients
Regeneron's Libtayo Cuts Death Risk 37% in High-Risk Skin Cancer Trial Follow-up
Reuters  ·  10-25 17:15
Regeneron's Libtayo Cuts Death Risk 37% in High-Risk Skin Cancer Trial Follow-up
Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)
GlobeNewswire  ·  10-25 17:15
Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)
Amgen and AstraZeneca Combo Extends Small Cell Lung Cancer Survival by Eight Months, Cutting Death Risk by 58%
Stock News  ·  10-25 10:50
Amgen and AstraZeneca Combo Extends Small Cell Lung Cancer Survival by Eight Months, Cutting Death Risk by 58%
Amgen: Grade 3 or Higher Adverse Events Occurred in 20.9% with Imdelltra Plus Imfinzi vs 10.8% with Imfinzi Alone
THOMSON REUTERS  ·  10-24 22:30
Amgen: Grade 3 or Higher Adverse Events Occurred in 20.9% with Imdelltra Plus Imfinzi vs 10.8% with Imfinzi Alone
Amgen: Imdelltra Plus Durvalumab Extends Median Overall Survival to 21.1 Months vs 12.7 Months with Durvalumab Alone
THOMSON REUTERS  ·  10-24 22:30
Amgen: Imdelltra Plus Durvalumab Extends Median Overall Survival to 21.1 Months vs 12.7 Months with Durvalumab Alone
Amgen: Imdelltra in Combination with Imfinzi Reduced Risk of Death by 58% in First-Line Extensive Stage Small Cell Lung Cancer
THOMSON REUTERS  ·  10-24 22:30
Amgen: Imdelltra in Combination with Imfinzi Reduced Risk of Death by 58% in First-Line Extensive Stage Small Cell Lung Cancer
Amgen Drug Combined with Immunotherapy Extends Survival in Lung Cancer Trial
Reuters  ·  10-24 22:30
Amgen Drug Combined with Immunotherapy Extends Survival in Lung Cancer Trial
Amgen: Nearly 80% of Patients on Imdelltra-Imfinzi Alive at One Year vs 53% with Durvalumab Alone & Progression-Free Survival More than Tripled
THOMSON REUTERS  ·  10-24 22:30
Amgen: Nearly 80% of Patients on Imdelltra-Imfinzi Alive at One Year vs 53% with Durvalumab Alone & Progression-Free Survival More than Tripled
Amgen: Safety Profile of Imdelltra in Combination with Durvalumab Consistent with Known Safety Profiles of Individual Medicines
THOMSON REUTERS  ·  10-24 22:30
Amgen: Safety Profile of Imdelltra in Combination with Durvalumab Consistent with Known Safety Profiles of Individual Medicines

Introduction

Company Name.
iShares Biotechnology ETF
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.
Issue price:
--